Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Purple Biotech Ltd. - American Depositary Shares (NQ:PPBT)

0.5773 -0.0278 (-4.59%)
Streaming Delayed Price Updated: 11:53 AM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Purple Biotech Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 Next >
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Unusual volume stocks in Friday's session
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill
Friday's session: top gainers and losers
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Let's take a look at the stocks that are in motion in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
Which stocks are gapping on Thursday?
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Purple Biotech Announces Pricing of Up To $18 Million Public Offering
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai
From Purple Biotech Ltd.
Via GlobeNewswire
Which stocks are moving before the opening bell on Wednesday?
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2
From Purple Biotech Ltd.
Via GlobeNewswire
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom
As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026. 
Via Stocktwits
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.